evERA Trial: What To Know About Potential Treatment Combination
- The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as estrogen receptor-positive (ER+) and HER2-negative (HER2-).
- A selective estrogen receptor degradant or SERD-based combination, which is taken orally, has outperformed the current standard of care, which is treating these patients with an endocrine therapy + everolimus if their cancer progresses after treatment with a CDK4/6 inhibitor.
- For patients, this means that when cancer has already outsmarted one line of hormone therapy, there may now be a new option, an all-oral regimen which can be taken at home.
- The benefits compared to the standard are modest: median progression-free survival (PFS) was 8.77 months with giredestrant (the SERD) + everolimus vs. 5.49 months with standard endocrine therapy + everolimus. Still, it’s a welcome new option for a difficult to treat disease.
To address the need for better treatment options, the evERA breast cancer trial tested an all-oral, next-generation hormone strategy using giredestrant (a selective estrogen receptor degradant or SERD) plus everolimus. Results show that this combination can keep the cancer controlled significantly longer than standard endocrine therapy plus everolimus in people whose disease has already progressed on a CDK4/6 inhibitor.
Read MoreWhat Do evERA’s Findings Mean For Patients?
evERA is a phase 3, global, randomized trial — it studied patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer who had already been treated with a CDK4/6 inhibitor plus endocrine therapy and whose cancer had progressed on that treatment.A total of 373 patients were randomized to either:
- Giredestrant + everolimus (all oral)
- Standard endocrine therapy (physician’s choice) + everolimus
Standard endocrine therapy typically meant an aromatase inhibitor like exemestane or other guideline-accepted options.
Giredestrant is an oral selective estrogen receptor degrader (SERD), a newer class of drugs that not only blocks the estrogen receptor but also marks it for destruction, which may help in tumors that have become resistant to older hormone pills.
The main outcome evERA looked at was progression-free survival (PFS), or how long people lived without their cancer growing or causing death.
Here’s what the trial showed:
- Median PFS was 8.77 months with giredestrant + everolimus vs. 5.49 months with standard endocrine therapy + everolimus.
- This translates to a 44% reduction in the risk of progression or death.
- In tumors with ESR1 mutations (a common resistance mutation after aromatase inhibitors), median PFS was 9.99 months in the giredestrant group vs. 5.45 months with standard endocrine + everolimus.
- That’s a 62% reduction in the risk of progression or death.
For patients whose cancer has already “broken through” a CDK4/6 inhibitor, evERA shows that an oral SERD-based regimen can almost double the time before the next progression, especially if the tumor carries an ESR1 mutation (one of the toughest resistance patterns we see).
Overall survival (OS), or whether people actually live longer, is still being followed. Early analyses show a “clear positive trend” favoring giredestrant + everolimus, but the data are not yet mature, so researchers can’t say definitively that the combo improves OS.
Still, the strong PFS improvement, especially in ESR1-mutant disease, is a big signal that this regimen is doing something clinically meaningful in a setting where options are limited.
Side Effects: What To Watch For
Because evERA added a new SERD but kept everolimus, the side-effect profile looks very similar to what was already known about everolimus-based regimens, with no new safety signals reported.
Common issues with everolimus-containing therapy include:
- Mouth sores (stomatitis)
- Fatigue
- Diarrhea
- Rash
- High blood sugar or high cholesterol
- Low blood counts
Giredestrant, as an endocrine drug, tends to carry side effects familiar from hormone therapy, such as hot flashes, joint aches, and mild GI symptoms, and was generally well-tolerated with a safety profile consistent with prior endocrine therapies.
In evERA, the rates of adverse events were similar between arms and no new or unexpected toxicities emerged. The combination was described as “well-tolerated” in presentations and press materials.
For patients, this means the main trade-off is not about brand-new dangers, but about whether the added benefit in cancer control is worth accepting the known day-to-day burdens of an everolimus-based regimen (lab monitoring, mouth care, managing fatigue and GI effects).
Questions To Ask Your Doctor
- Do my cancer’s features and my treatment path make me a good candidate for the giredestrant + everolimus combination?
- What are the benefits vs. potential risks of the giredestrant + everolimus combination?
- How would this treatment change my everyday life?
- How will I be monitored while undergoing this treatment?
Learn more about SurvivorNet's rigorous medical review process.
